# Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

> **NCT04504513** · — · APPROVED_FOR_MARKETING · sponsor: **G1 Therapeutics, Inc.**

## Conditions studied

- Myelosuppression Adult
- Chemotherapeutic Toxicity
- Small Cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib

## Key facts

- **NCT ID:** NCT04504513
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504513, "Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04504513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*